BioSpace News Archive

Medicenna Therapeutics Corp. announced that it will be presenting two abstracts, including an oral podium presentation, at the Annual Meeting of the American Society of Clinical Oncology to be held in Chicago from May 31 – June 4, 2024.

IDEAYA Biosciences, Inc. announced that interim results from the investigator-sponsored Phase 2 trial evaluating darovasertib safety and efficacy as neoadjuvant/adjuvant treatment in uveal melanoma have been selected for an oral presentation at the 2024 American Society of Clinical Oncology Annual Meeting taking place May 31-June 4, 2024 in Chicago, Illinois.

Nuvation Bio Inc. announced that updated data from the Phase 2 TRUST-I clinical study evaluating taletrectinib in patients in China with ROS1-positive non-small cell lung cancer will be reported in an oral presentation at the 2024 American Society of Clinical Oncology Annual Meeting taking place May 31-June 4, 2024 in Chicago, Illinois.

HighField Biopharmaceuticals announced that two HighField abstracts have been accepted with one poster presentation at the American Society of Clinical Oncology annual meeting May 31-June 4, 2024, in Chicago, IL.

Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1 trial of CLN-619 in patients with advanced solid tumors will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 31-June 4, 2024.

Dizal (SSE:688192) announced today that two abstracts featuring the latest data on sunvozertinib in non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (exon20ins) mutations will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on May 31 through June 4 in Chicago.

BioInvent International AB announced that two abstracts for its two leading assets, BI-1808 and BI-1206, have been selected for presentation at ASCO 2024.

Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from May 31 to June 4.

The global breast cancer diagnostics market was valued at USD 4.49 billion in 2023 and is expected to reach over USD 9.00 billion by 2033, poised to grow at a noteworthy CAGR of 7.2% from 2024 to 2033 North America dominated the market with a revenue share of 46.00% in terms of revenue in 2023.

Scientists have long known that our brains are organized into specialized areas, each responsible for distinct tasks. The visual cortex processes what we see, for instance, while the motor cortex governs movement.